Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands

What is it about?

What is already known about this subject?
•	Choosing therapies for type 2 diabetes that are both effective and cost-effective is vital as healthcare systems worldwide aim to maximize health of the population, and the World Health Organization recommends the use of cost-effectiveness analysis to ensure that interventions funded by a healthcare system represent good value for money. The cost-effectiveness of once-weekly semaglutide, a novel glucagon-like peptide-1 receptor agonist, has been assessed in a number of countries, but numerous factors may influence the cost-effectiveness of interventions in different settings. The aim of the present analysis was to assess the cost-effectiveness of once-weekly semaglutide from a societal perspective in the Netherlands.

What are the new findings?
•	Projections of outcomes over patient lifetimes suggest that once-weekly semaglutide 0.5 mg and 1 mg are likely to improve clinical outcomes for patients with type 2 diabetes compared with insulin glargine U100 and dulaglutide. Compared with insulin glargine U100, improvements in clinical outcomes came at an increased cost, but once-weekly semaglutide was considered cost-effective, even at the lowest willingness-to-pay threshold identified in the Netherlands. Improvements came at a reduced cost from a societal perspective versus dulaglutide, and therefore once-weekly semaglutide was considered dominant. 

How might these results change the focus of research or clinical practice?
•	Use of once-weekly semaglutide for treatment of patients with type 2 diabetes is likely to be a good use of healthcare resources in the Netherlands.


Featured Image